Онкогематология (Jun 2017)

MUCORMYCOSIS IN ONCOHEMATOLOGY PATIENTS (results of the prospective study)

  • N. N. Klimko,
  • S. N. Khostelidi,
  • O. V. Shadrivova,
  • T. S. Bogomolova,
  • Y. L. Avdeenko,
  • A. G. Volkova,
  • M. O. Popova,
  • I. A. Mihailova,
  • A. S. Kolbin,
  • E. G. Boychenko,
  • N. V. Medvedeva,
  • E. I. Podoltseva,
  • A. V. Klimovich,
  • M. B. Belogurova,
  • I. S. Zuzgin,
  • O. S. Uspenskaya,
  • V. N. Semelev,
  • N. I. Ponomoreva,
  • G. K. Abdilova,
  • L. S. Zuborovskaya,
  • B. V. Afanasiev

DOI
https://doi.org/10.17650/1818-8346-2017-12-2-14-22
Journal volume & issue
Vol. 12, no. 2
pp. 14 – 22

Abstract

Read online

In 2004–2016 we prospectively observed 59 oncohematology patients with mucormycosis; 21 children and 38 adults. The most frequent underlying diseases were acute myeloid leukemia and acute lymphoblastic leukemia (64 %); and main risk factors were сytostatic chemotherapy and allogeneic HSCT with prolonged (median – 30 days) neutropenia and lymphocytopenia. The etiology agents were Rhizopus spp. (47 %); Rhizomucor spp. (28 %); Lichtheimia corуmbifera (17 %) and Mucor spp. (8 %). Lichtheimia corуmbifera was found more often in children; Rhizopus and Mucor spp. in adults. Pulmonary mucormycosis was main clinical form (73 %); and ≥2 organs involvement was noted in 44 % patients. Antifungal therapy was used in 78 % patients; surgery – in 47 %. In treated with antifungals patients 12 weeks overall survival was 59 %. The positive prognostic factors were remission of underlying disease and combination antifungal therapy.

Keywords